Pharma News

In its final analysis of Pfizer Inc. 's widely used drug for transthyroid amyloid cardiomyopathy (ATRCM), the U.S. drug cost regulator called for a reduction of at least 85 percent from its current list price of nearly $268,000 a year to meet generally ac

After previous rejections, Astellas reached a milestone to celebrate over the weekend when its new stomach cancer treatment, Vyloy (zolbetuximab), received its first approval from the U.S. Food and Drug Administration (FDA).

Following a disappointing confirmatory clinical trial, Gilead Sciences has officially decided to withdraw its product Trodelvy from the bladder cancer treatment market in the United States. The decision was announced Friday by the California-based biotech

Last year, Novo Nordisk's new hemophilia treatment Concizumab won approval from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) after being rejected by the US Food and Drug Administration (FDA). Meanwhile, PTC Therape

Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign to combat weight bias and end the lifelong stigma that people with obesity suffer in multiple areas, including health care, employment, education and media coverag

French pharmaceutical giant Sanofi has announced that it is in advanced talks with prominent US investment firm Clayton Dubilier & Rice (CD&R) to explore the possible sale of a 50% controlling stake in its consumer healthcare business Opella.

Merck announced Thursday that its investigational antibody treatment, clesrovimab, demonstrated a 60.4 percent effectiveness in reducing infections associated with a specific type of respiratory syncytial virus (RSV) in infants.

The Czech government has officially identified the pharmaceutical industry as a strategic industry in a move aimed at reducing dependence on non-EU imports, strengthening the national health system and preventing potential drug shortages.

The European Union's ban on a chemical called Triton™X-100 has already had a profound impact on the biopharmaceutical manufacturing industry worldwide.

On October 16, 2024, global pharmaceutical company GSK announced that the US Food and Drug Administration (FDA) has officially accepted their New Drug marketing application (NDA) for Gepotidacin and granted the drug priority review.

German tech giant Merck has revised its medium-term growth targets for its life sciences and healthcare businesses, anticipating improved growth prospects in the Chinese market.

Novartis is trying to do everything possible to keep a generic version of its blockbuster heart failure drug Entresto off the U.S. market. Despite numerous legal hurdles, the company has failed to gain regulatory approval.

On October 15, 2024, TRIANA Biomedicines announced a major announcement that it has entered into a strategic collaboration and licensing agreement with world-renowned pharmaceutical giant Pfizer.

The British government is planning a study to assess whether a new weight-loss drug from US pharmaceutical giant Eli Lilly can help people regain their ability to work and have a positive impact on tackling high rates of long-term disease.

India's position as the world's third largest producer and core supplier of generic drugs plays a pivotal role in the global pharmaceutical sector and brings significant economic benefits to global healthcare systems, particularly in the United States.

Johnson & Johnson raised its 2024 profit and sales forecast on Tuesday, following strong oncology drug sales and quarterly results that beat Wall Street expectations.

Bayer AG (BAYGn.DE) announced on Monday that it has submitted an application to the European Union's drug regulator for approval of its product Nubeqa, also known as darolutamide, in combination with androgen deprivation therapy (ADT).

At the 29th Brazilian Congress of Entomology (CBE 2024), Bayer officially launched its first ketoenol insecticide, Plenexos, marking an important breakthrough for the company in this field.

In Monday's deal, Vanda Pharmaceutical Inc categorically rejected a second takeover proposal from Britain's Cycle Pharmaceuticals that valued the company at $8 per share.

Director-General Tedros noted that the COVID-19 pandemic has highlighted the importance of health issues to global security and prosperity, so support and investment in WHO is critical.